Intestinal crosstalk between bile acids and microbiota in irritable bowel syndrome

Intestinal crosstalk between bile acids and microbiota in irritable bowel syndrome
复制标题

DOI:
10.1111/jgh.16159
复制
发表时间:
2023-03
影响因子:
4.1
通讯作者:
Xuehong Deng;Lin-zhi Xiao;Mei-Ching Luo;Peiwei Xie;Lishou Xiong
Xuehong Deng;Lin-zhi Xiao;Mei-Ching Luo;Peiwei Xie;Lishou Xiong
中科院分区:
医学3区
文献类型:
--
作者:
Xuehong Deng;Lin-zhi Xiao;Mei-Ching Luo;Peiwei Xie;Lishou Xiong

文献摘要

相似文献

肠易激综合征(IBS)是一种较为常见的肠道菌群失调的功能性胃肠病。胆汁酸、肠道菌群和宿主之间存在密切而复杂的相互作用,在调节宿主免疫和代谢稳态中起着核心作用。最近的研究表明,胆汁酸-肠道菌群轴在IBS患者的发展中起着关键作用。为了研究胆汁酸在IBS发病机制中的作用并提出潜在的相关临床意义,我们对胆汁酸和肠道微生物群之间的肠道相互作用进行了文献检索。胆汁酸和肠道微生物群之间的肠道串扰形成了IBS的组成和功能改变,表现为肠道微生物生态失调,胆汁酸途径紊乱和微生物代谢产物的改变。胆汁酸通过改变法尼醇X受体和G蛋白偶联受体共同参与IBS的发病机制。针对胆汁酸及其受体的诊断标记物和治疗在IBS的管理中显示出有希望的潜力。胆汁酸和肠道微生物群在IBS的发展中起着关键作用,并成为治疗的有吸引力的生物标志物。针对胆汁酸及其受体的个体化治疗可能提供重要的诊断,需要进一步研究。
Irritable bowel syndrome (IBS) is a relatively common functional gastrointestinal disease with a disturbance of intestinal bacteria. Bile acids, gut microbiota, and the host have close and complex interactions, which play a central role in modulating host immune and metabolic homeostasis. Recent studies suggested that the bile acid–gut microbiota axis played a key role in the development of IBS patients. In order to investigate the role of bile acids in the pathogenesis of IBS and present potentially relevant clinical implications, we conducted a literature search on intestinal interactions between bile acid and gut microbiota. The intestinal crosstalk between bile acids and gut microbiota shapes the compositional and functional alterations in IBS, manifesting as gut microbial dysbiosis, disturbed bile acid pathway, and alteration of the microbial metabolites. Collaboratively, bile acid conducts the pathogenesis of IBS through the alterations of the farnesoid‐X receptor and G protein‐coupled receptor. Diagnostic markers and treatments targeting the bile acids and its receptor showed promising potential in the management of IBS. Bile acids and gut microbiota play a key role in the development of IBS and make attractive biomarkers for treatments. Individualized therapy aiming at bile acids and its receptor may provide significant diagnostic and requires further investigation.